Pharmaceutical R&D is organized around prioritized investments, delivering on assets with the greatest return of investments. Linear sequencing of trials and financial risks are determinants of speed in an enterprise. There is less flexibility in leveraging expertise around priorities that are thrust on the system by external forces. This commentary provides an insight into enabling … Continued
As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among options for accelerated development is the evaluation of drug combinations in the absence of prior monotherapy data. This approach is appealing for a number of reasons. First, combining two or … Continued
Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for repurposing to treat COVID-19. This number will grow thanks to the use of new combination therapies discovered under an aggressive, disciplined, and quantitative approach to evaluating candidates called model-informed drug development (MIDD)…
We hypothesized that viral kinetic modeling could be helpful to prioritize rational drug combinations for COVID‐19. The aim of this research was to use a viral cell cycle model of SARS‐CoV‐2 to explore the potential impact of drugs, or combinations of drugs that act at different stages in the viral life cycle might have on … Continued
A successful cocktail would also serve us in the long-run to treat the impacts of Covid-19 and keep those who are most vulnerable, the elderly and those with pre-existing conditions, more resilient against serious illness or death….
Research Database to Quantify Impact of Potential COVID-19 Treatments,
with Results from Over 500 Clinical Trials and Observational Studies Over the Next Three Months
The COVID-19 pandemic has turned our lives upside down and so many questions remain, including around how it is affecting health technology assessment (HTA) bodies. HTA bodies report that they have had to ramp up and are increasingly relying on smaller evidence sets. Going forward the priorities for and speed of assessments, particularly for vaccines, is likely to increase. On top of this, economies struggling with significantly increased levels of debt may respond by tightening budgets outside communicable diseases thus affecting assessment priorities, methods and recommendations.